Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3 Angiotensin signalling in adiporenal crosstalk

Published byἩσαΐας Δασκαλόπουλος Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 3 Angiotensin signalling in adiporenal crosstalk"— Presentation transcript:

1 Figure 3 Angiotensin signalling in adiporenal crosstalk
Figure 3 | Angiotensin signalling in adiporenal crosstalk. In addition to the liver, adipose tissue produces considerable amounts of angiotensinogen (AGT), which further converts to the active peptide angiotensin II (ANG II). Two types of ANG II receptors exist — type-1 angiotensin II receptors (AT1) and type-2 angiotensin II receptors (AT2) — which are present in both the kidney and adipose tissue and act antagonistically. Activation of AT1 signalling promotes macrophage infiltration in the kidney and adipose tissue and shifts polarization of M2 macrophagestowards a pro-inflammatory M1 phenotype. Thus, ANG II–AT1 signalling accelerates inflammation and ultimately leads to glomerular injury and albuminuria. Moreover, alterations in adipose tissue function in the presence of ANG II, including adipose inflammation and hypertrophy, further exaggerate kidney injury. AT2 antagonizes AT1 signalling. In addition, AT1 signalling is blocked by type-1 angiotensin II receptor-associated protein (ATRAP), which increases internalization and desensitization of AT1. Zhu, Q. & Scherer, P. E. (2017) Immunologic and endocrine functions of adipose tissue: implications for kidney disease Nat. Rev. Nephrol. doi: /nrneph

Download ppt "Figure 3 Angiotensin signalling in adiporenal crosstalk"

Similar presentations

The Road To Metabolic syndrome

The Road To Metabolic syndrome
Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.

Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.
Figure 6 Effects of adiponectin on podocyte function

Figure 6 Effects of adiponectin on podocyte function
Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.
Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.
Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Expression of coagulation protease receptors in renal cells
Figure 4 Interactions between adipose, the microbiome and kidney

Figure 4 Interactions between adipose, the microbiome and kidney
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 1 Mechanisms of kidney injury in the setting of obesity
Figure 2 Physiological changes in the renal system in pregnancy

Figure 2 Physiological changes in the renal system in pregnancy
Figure 2 Proinflammatory mechanisms in CKD

Figure 2 Proinflammatory mechanisms in CKD
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 3 The fat–intestine–kidney axis

Figure 3 The fat–intestine–kidney axis
Viper venom for diabetic nephropathy

Viper venom for diabetic nephropathy
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.
Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)
Figure 2 The network of chronic diseases and their mutual influences

Figure 2 The network of chronic diseases and their mutual influences
Figure 2 Three distinct mechanisms of activation of

Figure 2 Three distinct mechanisms of activation of
Figure 1 The sensory and secretory function of the L cell

Figure 1 The sensory and secretory function of the L cell

Similar presentations

Ads by Google